Abstract
Preclinical data suggest that one method of inducing autoimmunity to tumor is the administration and subsequent withdrawal of cyclosporine A following chemotherapy and that this effect may be enhanced with interferon and interleukin-2. Consequently, we performed a phase II trial in patients with advanced melanoma to explore this approach. Thirty-three patients were treated with BCNU (150 mg/m2 iv every 8 weeks), cisplatin (25 mg/m 2 iv days 1-3) every 4 weeks, DTIC (220 mg/m2 iv days 1-3 every 4 weeks) along with tamoxifen (10 mg po BID days 1-4). Cyclosporine A at 3 mg/kg/day in two divided doses was given on days 4-21, alpha-interferon 1 million units/m2 subcutaneously every other day on days 4-21 and interleukin-2 1 million units/m2 BID subcutaneously days 21-28 were also given. Of the 33 patients, 3 patients (9%) had complete response and 8 patients (24%) had a partial response for a total response rate of 33% (95% confidence interval 18-52%). Median duration of response was 17 months (range 3+ to 24+ months). Six patients continue to show no signs of tumor progression for 3+, 5+, 10+, 24+, 60+, and 72+ months. Toxicity was generally well tolerated and included myelosuppression and fatigue. This regimen is feasible and generally tolerable and has produced an antitumor response rate comparable with inpatient biochemotherapy regimens.
| Original language | English |
|---|---|
| Pages (from-to) | 3-8 |
| Number of pages | 6 |
| Journal | Cancer Investigation |
| Volume | 23 |
| Issue number | 1 |
| DOIs | |
| State | Published - Mar 21 2005 |
Fingerprint
Keywords
- Cyclosporine
- Interferon
- Interleukin
- Melanoma
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Cyclosporine A, alpha-interferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen : A phase II study in advanced melanoma. / Feun, Lynn G; Marini, Angela; Moffat, Frederick L; Savaraj, Niramol; Hurley, Judith; Mazumder, Amitabha.
In: Cancer Investigation, Vol. 23, No. 1, 21.03.2005, p. 3-8.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cyclosporine A, alpha-interferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen
T2 - A phase II study in advanced melanoma
AU - Feun, Lynn G
AU - Marini, Angela
AU - Moffat, Frederick L
AU - Savaraj, Niramol
AU - Hurley, Judith
AU - Mazumder, Amitabha
PY - 2005/3/21
Y1 - 2005/3/21
N2 - Preclinical data suggest that one method of inducing autoimmunity to tumor is the administration and subsequent withdrawal of cyclosporine A following chemotherapy and that this effect may be enhanced with interferon and interleukin-2. Consequently, we performed a phase II trial in patients with advanced melanoma to explore this approach. Thirty-three patients were treated with BCNU (150 mg/m2 iv every 8 weeks), cisplatin (25 mg/m 2 iv days 1-3) every 4 weeks, DTIC (220 mg/m2 iv days 1-3 every 4 weeks) along with tamoxifen (10 mg po BID days 1-4). Cyclosporine A at 3 mg/kg/day in two divided doses was given on days 4-21, alpha-interferon 1 million units/m2 subcutaneously every other day on days 4-21 and interleukin-2 1 million units/m2 BID subcutaneously days 21-28 were also given. Of the 33 patients, 3 patients (9%) had complete response and 8 patients (24%) had a partial response for a total response rate of 33% (95% confidence interval 18-52%). Median duration of response was 17 months (range 3+ to 24+ months). Six patients continue to show no signs of tumor progression for 3+, 5+, 10+, 24+, 60+, and 72+ months. Toxicity was generally well tolerated and included myelosuppression and fatigue. This regimen is feasible and generally tolerable and has produced an antitumor response rate comparable with inpatient biochemotherapy regimens.
AB - Preclinical data suggest that one method of inducing autoimmunity to tumor is the administration and subsequent withdrawal of cyclosporine A following chemotherapy and that this effect may be enhanced with interferon and interleukin-2. Consequently, we performed a phase II trial in patients with advanced melanoma to explore this approach. Thirty-three patients were treated with BCNU (150 mg/m2 iv every 8 weeks), cisplatin (25 mg/m 2 iv days 1-3) every 4 weeks, DTIC (220 mg/m2 iv days 1-3 every 4 weeks) along with tamoxifen (10 mg po BID days 1-4). Cyclosporine A at 3 mg/kg/day in two divided doses was given on days 4-21, alpha-interferon 1 million units/m2 subcutaneously every other day on days 4-21 and interleukin-2 1 million units/m2 BID subcutaneously days 21-28 were also given. Of the 33 patients, 3 patients (9%) had complete response and 8 patients (24%) had a partial response for a total response rate of 33% (95% confidence interval 18-52%). Median duration of response was 17 months (range 3+ to 24+ months). Six patients continue to show no signs of tumor progression for 3+, 5+, 10+, 24+, 60+, and 72+ months. Toxicity was generally well tolerated and included myelosuppression and fatigue. This regimen is feasible and generally tolerable and has produced an antitumor response rate comparable with inpatient biochemotherapy regimens.
KW - Cyclosporine
KW - Interferon
KW - Interleukin
KW - Melanoma
UR - http://www.scopus.com/inward/record.url?scp=14844304333&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=14844304333&partnerID=8YFLogxK
U2 - 10.1081/CNV-200046368
DO - 10.1081/CNV-200046368
M3 - Article
C2 - 15779861
VL - 23
SP - 3
EP - 8
JO - Cancer Investigation
JF - Cancer Investigation
SN - 0735-7907
IS - 1
ER -